Corient Private Wealth
SPRY icon

Corient Private Wealth’s ARS Pharmaceuticals SPRY Stock Holding History

Corient Private Wealth’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$650K Buy
+80,943
New +$776K ﹤0.01% 1889
2023
Q4 		– Sell
-10,042
Closed -$38K – 2344
2023
Q3 		$38K Buy
+10,042
New +$65.9K ﹤0.01% 2086

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Corient Private Wealth's SPRY Position: Q1 2026 in Review

Corient Private Wealth opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 80,943 shares worth $650K. The stake represents ﹤0.01% of the portfolio and ranks #1889 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in SPRY as recently as Q3 2023.

Corient Private Wealth first reported a position in SPRY in Q3 2023 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Corient Private Wealth held 80,943 shares of ARS Pharmaceuticals worth $650K as of Q1 2026.
  • ARS Pharmaceuticals was a new Corient Private Wealth position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1889 holding.
  • Corient Private Wealth first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.